February 8, 2012
| Bio-IT World > Short News & Analysis


Short News & Analysis



May 28, 2009 | Compugen Reports Promising In Vivo Results
Compugen reported positive in-vivo results for CGEN-856 and CGEN-857, two novel peptide agonists of the MAS G-protein coupled receptor (GPCR) which the company discovered using its in silico platform. Recently studies demonstrated the cardioprotective and anti-hypertensive effects of these two product candidates, says Compugen.

Compugen VP for R&D Dr. Anat Cohen Dayag said, “All of our product candidates, including CGEN-856 and 857, begin purely as computer generated theoretical predictions. Thus we are extremely pleased by the rapidly growing amount of experimental validation supporting the validity of our in silico predictions, both in terms of breadth of applications and depth of confirmation.” Read release.
        
Genetic Anti-Discrimination Law Takes Affect
A long-awaited federal law that shields people from genetic discrimination delivered its first layer of protection last Thursday. The measure will prevent health insurers from denying coverage, adjusting premiums or otherwise discriminating based on genetic information, a term that includes family history. The law does not apply to life insurers, according to a Forbes/AP report. Read article.

Switzerland Grants $25M for Systems Biology Studies
The Swiss National Science Foundation has granted CHF27.5 million ($25 million) to fund several biomedical research and genomics and technology development grants focused on systems biology. The SNSF SystemsX.ch program has approved six projects that will fund research coordinated by the Swiss Institute for Bioinformatics; the Universities of Basel, Lausanne, Geneva, and Zurich; the Friedrich-Miescher Institute of the Novartis Research Foundation; and the Swiss Federal Institutes of Technology. Funding is part of a CHF100 million systems biology program funded by the Swiss government that runs between 2008 and 2011. Read GenomeWeb report.

Asubio Pharma to Use Genedata Biomarker Discovery Platform
Asubio Pharma, a wholly-owned subsidiary of Daiichi Sankyo, is using the Genedata Expressionist system to support its compound profiling and biomarker discovery process. "We were looking for a bioinformatics solution to manage a huge volume of DNA array data generated internally at Asubio as well as to integrate additional external molecular profiling data,” said Michinori Kadokura, associate senior researcher at Asubio Pharma. Read release.

NIH Grants $2M for Development of e-Microscope to Film Biological Processes
The plan is to extend the capabilities of a powerful new imaging tool called the dynamic transmission electron microscope or DTEM. These instruments can snap 10 to 100 images per millionth of a second, while capturing details as small as 10 nanometers, or about four times the diameter of a DNA molecule. Read article.

Ingenuity Systems Releases IPA 7.5
The latest version of the software enables researchers to quickly integrate and understand multiple lines of experimental evidence from either publicly available or proprietary data sources. "These enhancements really position IPA as a powerful tool for disease research," stated Brigitte Ganter, director of product management, Ingenuity Systems. Additional new tools in IPA 7.5 enable researchers to bring a wide range of data together for better biological understanding: updated mapping and comparison tools for rapid data assessment; additional Path Designer tools for customization of pathway graphics; SBML pathway import (beta) for the creation of custom pathway libraries; new disease-focused content including 46 new signaling pathways. Read Release.

Genego and Omicsoft Announce Integration
GeneGo, a leading provider of pathway data mining & analysis solutions, and OmicSoft Corporation, provider of visualization and analysis software for high dimensional data, announced the integration of the MetaCore pathway analysis platform with Array Studio. “Array Studio is a powerful analysis platform and we have mutual customers that this integration will benefit,” said Julie Bryant, VP of Business Development at GeneGo. Read release.

--

This article first appeared in Bio-IT World’s Predictive Biomedicine newsletter. Click here for a free subscription.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi whp 2
Managing the Modern Genomics Data Flood
Sponsored by SGI

Managing and storing the perfect storm of multi-disciplined data pouring from next generation sequencers and other omics instruments is a central challenge in life sciences. Discover in this paper how the SGI ArcFiniti storage solution, optimized for unstructured genomics and life sciences data can: 

  • Reduce costs, proactively protect data integrity, and deliver the high performance I/O required for genomics data processing and analysis.  
  • Effectively manage capacities from 156TB to 1.4PB as a disk based, integrated hardware and software platform 


sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .